The biopharmaceutical industry faces some major bottlenecks in the development lifecycle that can only be overcome by effective digital transformation. According to research by pharmamanufacturing.com, in excess of 60% of biopharma organizations are still managing many of their critical steps with paper and Microsoft Office, while struggling to integrate the expanding ecosystem of equipment and data – literarily wasting 30–40% of their time on basic data administration and documentation.
At the heart of the problem is the need for a digital transformation of the development lifecycle, because in a world of automation, parallelization and digitalization, the main barrier to accelerated biopharmaceuticals is – ironically – the fragility of a lifecycle managed with paper records and silos of data. Especially when contextualized data is the rocket fuel needed to drive speed and innovation.
We accepted the challenge and created a BioPharmaceutical Lifecycle Management (BPLM) system that integrates data from all instruments, all equipment and all software to shorten time to market for biopharmaceuticals like vaccines and therapies.
IDBS polar accelerates biopharmaceutical development into the digital age with a unique software platform designed to remove roadblocks and deliver deep insights that drive innovation – for faster and more cost-effective access to life changing therapies.
IDBS Polar is the world’s first BioPharmaceutical Lifecycle Management (BPLM) system – a cloud-based platform that eliminates repetitive manual tasks, allowing you to efficiently execute your processes while curating the data you need to reduce time-to-market by tackling the biggest challenges in process design, optimization, scale-up and technology transfer.
IDBS Polar rests upon three pillars: best practice out-of-the-box workflows exclusively designed for biopharma development, full integration of all systems and equipment for access to your complete data continuum, and advanced tools for fast analytics, insight and technology transfer based on high-quality, contextualized data.
The result is a dramatic reduction of time to market by up to three years, and a much greater potential to continuously learn, model, simulate and predict the future to further improve development cycles.
Fast deployment and up to six times shorter time to value than traditional software platforms.
Key benefit
Dramatically reduced time-to-market
Key benefit
Full integration of all systems and equipment for contextualized, high-quality data
Key benefit
Best practice out-of-the-box workflows exclusively designed for biopharma development and bioanalysis
Key benefit
Advanced tools for meaningful analytics and faster insights
Key benefit
Faster technology transfer
Key benefit
Improved modelling & simulation for predictive value
Key benefit
Fast deployment and six times shorter time-to-value
Global biotech transformed its R&D process with E‑WorkBook. Data input, capture and search time slashed by 75%. Global Biotech is a pioneer global distributor for biological technologies. They distribute high-quality and precision products and technologies to neuroscience…
